HIPK2 and cancer cell resistance to therapy

Future Oncology

Volumn 4, Issue 6, 2008, Pages 751-754

  Krieghoff Henning, Eva ^a   Hofmann, Thomas G ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXIN; BETA CATENIN; BINDING PROTEIN; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DOXORUBICIN; HIGH MOBILITY GROUP A1A PROTEIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; RING FINGER PROTEIN; ROSCOVITINE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX1; VASCULOTROPIN; CARRIER PROTEIN; HIPK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ACETYLATION; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; CANCER CELL CULTURE; CARCINOGENESIS; CHEMOSENSITIVITY; DOWN REGULATION; EDITORIAL; ENZYME ACTIVATION; HUMAN; IONIZING RADIATION; LEUKEMOGENESIS; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SKIN CANCER; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; UTERINE CERVIX CANCER; ANIMAL; DRUG RESISTANCE; PHYSIOLOGY;

ANIMALS; CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTEIN-SERINE-THREONINE KINASES;

EID: 61449444074     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.6.751     Document Type: Editorial

References (25)

1. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y: Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem. 273, 25875-25879 (1998).
2. Hofmann TG, Moller A, Sirma H et al.: Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4, 1-10 (2002).
3. D'Orazi G, Cecchinelli B, Bruno T et al.: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Set 46 and mediates apoptosis. Nat. Cell Biol. 4, 11-19 (2002).
4. Dauth I, Kruger J, Hofmann TG: Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res. 67, 2274-2279 (2007).
5. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G: Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp. Cell Res. 293, 311-320 (2004).
6. Gresko E, Roscic A, Ritterhoff S, Vichalkovski A, Del Sal G, Schmitz ML: Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J. 25, 1883-1894 (2006).
7. Wesierska-Gadek J, Schmitz ML, Ranftler C: Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J. Cell. Biochem. 100, 865-874 (2007).
8. Hofmann TG, Stollberg N, Schmitz ML, Will H: HIPK2 Regulates transforming growth factor-β-induced c-jun NH(2)- terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res. 63, 8271-8277 (2003).
9. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH: Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 115, 177-186 (2003).
10. Wang SY, Iordanov M, Zhang Q: c-Jun NH2-terminal kinase promotes apoptosis by down-regulating the transcriptional co-repressor CtBP. J. Biol. Chem. 281, 34810-34815 (2006).
11. Rui Y, Xu Z, Lin S et al.: Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J. 23, 4583-4594 (2004).
12. Pierantoni GM, Bulfone A, Pentimalli F et al.: The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem. Biophys: Res. Commun. 290, 942-947 (2002).
13. Li XL, Arai Y, Harada H et al.: Mutations of the HIPK2 gene in acute myeloid leukemia and myelolysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene 26(51), 7231-7239 (2007).
14. Wee HJ, Voon DC, Bae SC, Ito Y: PEBP2β/CBFβ-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112(9), 3777-3787 (2008).
15. Pierantoni GM, Rinaldo C, Mottolese M et al.: High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J. Clin. Invest. 117, 693-694 (2007).
16. Wei G, Ku S, Ma GK et al.: HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc. Natl Acad. Sci. USA 104, 13040-13045 (2007).
17. Al-Beiti MA, Lu X: Expression of HIPK2 in cervical cancer: correlation with clinicopathology and prognosis. Aust. NZ J. Obstet. Gynaecol. 48, 329-336 (2008).
18. Deshmukh H, Yeh TH, Yu J et al.: High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 27(34), 4745-4751. (2008).
19. Puca R, Nardinocchi L, Pistritto G, D'Orazi G: Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol. Oncol. 109, 403-410 (2008).
20. Puca R, Nardinocchi L, Gal H et al.: Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. 68, 3707-3714 (2008).
21. Zhang J, Pho V, Bonasera SJ et al.: Essential function of HIPK2 in TGFβ-dependent survival of midbrain dopamine neurons. Nat. Neurosci. 10, 77-86 (2007).
22. Choi DW, Seo YM, Kim EA et al.: Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1. J. Biol. Chem. 283, 4682-4689 (2008).
23. Winter M, Sombroek D, Dauth I et al.: Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat. Cell Biol. 10, 812-824 (2008).
24. Nakayama K, Frew IJ, Hagensen M et al.: Siah2 reguiates stability of pralyl-hydroxylases, controls HIF1α abundance, and modulates physiological responses to hypoxia. Cell 117, 941-952 (2004).
25. Schmidt RL, Park CH, Ahmed AU et al.: Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. Cancer Res. 67, 11798-11810 (2007).